MedTrace Logo

Cord Blood Transplantation for Patients With Cancer

NCT01359254 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-04-30

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.

Conditions

  • Hematological Disease

Interventions

DRUG

Melphalan

Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.

DRUG

Fludarabine

Fludarabine is given through the vein daily for 5 days.

DRUG

Antithymocyte Globulin (ATG)

ATG is given every other day for 4 days.

DRUG

Busulfan

Busulfan is given daily for 4 days.

DRUG

Total Body Irradiation (TBI)

TBI is given twice on the last day.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Andrew Artz, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-09-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01359254 on ClinicalTrials.gov